(Q36396522)

13 August 2017

1 reference

title

New drug candidates and therapeutic targets for tuberculosis therapy (English)

1 reference

13 August 2017

0 references

Ying Zhang

1

1 reference

PubMed ID

16478687

13 August 2017

Katrin Post-Martens

series ordinal

2

1 reference

PubMed ID

16478687

13 August 2017

Steven Denkin

series ordinal

3

1 reference

13 August 2017

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

11

1 reference

13 August 2017

1-2

1 reference

13 August 2017

21-27

1 reference

The growing burden of tuberculosis: global trends and interactions with the HIV epidemic

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Tuberculosis drug resistance: a global threat

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Persistent and dormant tubercle bacilli and latent tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

The magic bullets and tuberculosis drug targets.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

The search for new sterilizing anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Prospects for new antitubercular drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

TB drug discovery: addressing issues of persistence and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Current status and future development of antitubercular chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Genes required for mycobacterial growth defined by high density mutagenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Contribution of proton-translocating proteins to the virulence of Salmonella enterica serovars Typhimurium, Gallinarum, and Dublin in chickens and mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Susceptibility of Mycobacterium tuberculosis to weak acids

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Development potential of rifalazil

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Durable cure for tuberculosis: rifalazil in combination with isoniazid in a murine model of Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Oxazolidinones, a new class of synthetic antituberculosis agent in vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Synthesis and in vitro antimycobacterial activity of novel 3-(1H-pyrrol-1-yl)-2-oxazolidinone analogues of PNU-100480.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Activity of RBx 7644 and RBx 8700, new investigational oxazolidinones, against Mycobacterium tuberculosis infected murine macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Linezolid for the treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)--a report of ten cases

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Antituberculosis activity of certain antifungal and antihelmintic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Azole-antifungal binding to a novel cytochrome P450 from Mycobacterium tuberculosis: implications for treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Antimycobacterial activities of riminophenazines

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Combinatorial lead optimization of [1,2]-diamines based on ethambutol as potential antituberculosis preclinical candidates

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Medicine. New TB drug promises shorter, simpler treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Mycobacterium tuberculosis in the Extracellular Compartment: an Underestimated Adversary

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Genetic requirements for mycobacterial survival during infection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Designer arrays for defined mutant analysis to detect genes essential for survival of Mycobacterium tuberculosis in mouse lungs

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Prokaryotic toxin-antitoxin stress response loci

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Bacterial programmed cell death systems as targets for antibiotics.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Systems biology in drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Systematic discovery of multicomponent therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Microsphere technology for chemotherapy of mycobacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Therapy of tuberculosis in mice by DNA vaccination.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Protective effect of DNA vaccine during chemotherapy on reactivation and reinfection of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Immunology of tuberculosis and implications in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

Mutation of tlyA confers capreomycin resistance in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903626-3

7 January 2021

10.1016/S1359-6446(05)03626-3

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16478687